相关实验视频

Updated: May 29, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

针对HVEM-GPT2轴:一种新的T细胞激活和代谢重编程方法,用于治疗非小细胞肺癌

Yuanshan Yao¹, Chunji Chen^1,2, Bin Li²

¹Department of Thoracic Surgery, HuaDong hospital affiliated to Fudan University, Shanghai, China.

Cancer immunology, immunotherapy : CII

|February 4, 2025

概括

这项研究表明,HVEM-GPT2轴对非小细胞肺癌 (NSCLC) 的T细胞功能至关重要,提供了一个新的治疗点. 向HVEM可以增强T细胞活性并改善NSCLC治疗结果.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

免疫检查点路径是癌症免疫治疗的关键目标.
瘤微环境显著影响治疗疗效.
了解NSCLC中的HVEM等新目标至关重要.

研究的目的:

研究疹病毒进入媒介 (HVEM) 在非小细胞肺癌 (NSCLC) 微环境中的作用.
探索HVEM对T细胞功能和NSCLC进展的影响.
在HVEM路径中识别潜在的治疗点.

主要方法:

对HVEM表达的TCGA和TISCH数据集的分析.
多重体免疫组织化学 (mIHC) 用于空间分析.
在体外共同培养系统和体内小鼠模型.
基因表达 (qPCR),蛋白质分析 (西式涂抹) 和代谢分析 (OCR).
在机理学研究中使用RNA-seq,COIP,双露西法酶记者和CHIP-seq.

主要成果:

在NSCLC患者中,HVEM表达与免疫功能障碍相关.
主要在T细胞亚群 (CD8+和CD4+) 中表达HVEM,较高水平表明更好的预后.
受HVEM影响的激活T细胞抑制NSCLC的扩散和侵入.
HVEM对于T细胞的存活,激活和代谢重编程 (糖解) 是必不可少的.
在HVEM-GPT2轴中介于T细胞激活和代谢,GATA1调节HVEM表达.

结论:

在NSCLC微环境中,HVEM在调节T细胞功能方面发挥着重要作用.
在HVEM-GPT2轴代表了增强NSCLC癌症免疫治疗的有希望的治疗标.
向HVEM可以改善T细胞反应和NSCLC患者的治疗结果.

关键词:

在这里,HVEMEM HVEMEM 免疫治疗是一种免疫疗法.尤尔卡特细胞是Jurkat细胞.在NSCLCLC中,我们可以看到NSCLCLC.

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...